You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease…

Article metrics

Article menu

Download PDFPDF

XML
Neurology
Protocol
Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

 

Online download statistics by month:

Online download statistics by month: June 2021 to April 2024

AbstractFullPdf
Jun 202130292
Jul 2021559559133
Aug 202117116894
Sep 202116716868
Oct 202118818177
Nov 202116816568
Dec 2021797543
Jan 2022495237
Feb 2022665838
Mar 202210310135
Apr 202211611034
May 202214014553
Jun 2022938537
Jul 202212010441
Aug 2022817746
Sep 2022636337
Oct 2022918657
Nov 2022898550
Dec 20229713763
Jan 2023777138
Feb 2023846839
Mar 2023575234
Apr 2023666029
May 2023565230
Jun 2023433314
Jul 2023413822
Aug 2023676527
Sep 2023757124
Oct 202317115031
Nov 202327326231
Dec 2023755334
Jan 2024565030
Feb 2024716934
Mar 2024737179
Apr 2024514531
Total380636581540